8-K: Catalyst Pharmaceuticals Appoints Veteran Rare Disease Expert William Andrews as New Chief Medical Officer

Catalyst Pharmaceuticals, Inc. announced the retirement of its Chief Medical and Regulatory Officer, Dr. Gary Ingenito, and the immediate appointment of Dr. William Andrews, a seasoned biopharmaceutical executive with extensive rare disease experience, as the new Chief Medical Officer.

Summary

• Catalyst Pharmaceuticals, Inc. announced that Dr. Gary Ingenito, Chief Medical and Regulatory Officer, retired from his position on June 1, 2025.
• Dr. Ingenito's retirement was not due to any disagreements with the company, its management, or Board of Directors.
• Dr. Ingenito will continue to serve as a consultant to ensure a smooth transition.
• On June 2, 2025, Dr. William (Will) Andrews joined Catalyst Pharmaceuticals as the new Chief Medical Officer.
• Dr. Andrews brings 25 years of global biopharmaceutical experience, with a primary expertise in rare diseases spanning nearly 20 years.
• His experience includes clinical development, medical affairs, medical/commercial strategy, business development, drug safety, regulatory affairs, and leading seven therapeutic launches.
• Prior to Catalyst, Dr. Andrews served as CEO and President of Lighthouse Bio, Principal of Aletheia Lifesciences, and Chief Medical Officer at Flexion Therapeutics, Akcea Therapeutics, and Acer Therapeutics.
• Catalyst Pharmaceuticals was recognized on the Forbes 2025 list as one of America's Most Successful Mid-Cap Companies and on the 2024 Deloitte Technology Fast 500 list as one of North America's Fastest-Growing Companies.

Sentiment

Score: 8

Explanation: The document conveys a strong positive sentiment due to the appointment of a highly qualified and experienced Chief Medical Officer, a smooth transition process, and management's positive remarks about the company's 'exceptional financial performance' and growth trajectory.

Positives

• The appointment of Dr. William Andrews, a highly experienced biopharmaceutical executive with 25 years of global experience and a strong focus on rare diseases, is a significant positive for Catalyst Pharmaceuticals.
• Dr. Andrews' background includes leadership roles in clinical development, medical affairs, and successful therapeutic launches, which aligns well with Catalyst's focus on rare disease therapies.
• The smooth transition plan, with Dr. Ingenito continuing as a consultant, minimizes disruption.
• Management highlighted Catalyst's 'exceptional financial performance' and 'growing demand for our differentiated therapies', indicating strong underlying business health.
• Catalyst's recognition on the Forbes 2025 list as one of America's Most Successful Mid-Cap Companies and the 2024 Deloitte Technology Fast 500 list underscores its strong growth and market position.

Risks

• Forward-looking statements involve known and unknown risks and uncertainties, which may cause actual results to differ materially from forecasted results.
• Factors described in Catalyst's Annual Report on Form 10-K for the 2024 fiscal year, Quarterly Report on Form 10-Q for the first quarter of 2025, and subsequent SEC filings could adversely affect the company.

Future Outlook

Catalyst Pharmaceuticals aims to continue its exceptional financial performance, driven by its commercial strategy and growing demand for differentiated therapies. The company is also actively seeking to expand its global commercial footprint through strategic agreements.

Management Comments

• Richard J. Daly, President and Chief Executive Officer, stated: "We are pleased to welcome Dr. Andrews to Catalyst. In addition to his foundational work in clinical practice in some of the country's most prestigious hospitals, he brings significant experience in biopharmaceuticals to this role."
• Richard J. Daly also commented: "This is an exciting time to join Catalyst as we work to continue our exceptional financial performance that underscores the strength of our commercial strategy and the growing demand for our differentiated therapies that help patients live healthier lives."
• Richard J. Daly further added: "We would like to thank Dr. Gary Ingenito for his incredible service to Catalyst over the past ten years and congratulate him on his formidable career in the biopharmaceutical industry."

Industry Context

The appointment of a highly experienced Chief Medical Officer with a strong background in rare diseases aligns with the growing focus and investment in the rare disease therapeutic area within the biopharmaceutical industry. This strategic hire positions Catalyst to potentially enhance its clinical development pipeline and commercialization efforts in this specialized and often high-value market segment. The company's recognition on Forbes and Deloitte lists suggests it is outperforming many peers in terms of growth and success.

Comparison to Industry Standards

• Catalyst Pharmaceuticals was recognized on the Forbes 2025 list as one of America's Most Successful Mid-Cap Companies, indicating strong performance relative to other mid-capitalization companies.
• The company was also listed on the 2024 Deloitte Technology Fast 500 list as one of North America's Fastest-Growing Companies, suggesting its growth rate is among the top performers in the technology and life sciences sectors.

Management Changes

Stakeholder Impact

• Shareholders: The appointment of a highly experienced CMO is likely to be viewed positively, potentially enhancing confidence in the company's strategic direction and clinical development capabilities.
• Employees: A smooth leadership transition and the addition of a seasoned executive can provide stability and new strategic direction.
• Patients: The continued focus on rare diseases and the expertise of the new CMO could lead to further development and accessibility of differentiated therapies.

Next Steps

• Dr. Ingenito will continue to serve as a consultant to the Company to assist in a smooth transition.

Key Dates

Recommendation

Keywords

Catalyst Pharmaceuticals, CPRX, Chief Medical Officer, CMO, William Andrews, Gary Ingenito, Biopharmaceutical, Rare Disease, Executive Appointment, Management Change, SEC Filing, 8-K